The RLT Hub is your guide to understanding GEP-NETs, PSMA positive mCRPC and RLT
Great Britain Prescribing information for Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) can be found here.
Northern Ireland Prescribing information for Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) can be found here.
Prescribing information for Lutathera® (lutetium [177Lu] oxodotreotide) can be found here.
The RLT Hub was developed by Advanced Accelerator Applications, a Novartis company, to provide information to GB health professionals interested in radioligand therapy (RLT) to support the management of their patients with neuroendocrine tumours (NET) and prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
Site features
This site provides you with the relevant information and resources to guide your knowledge and understanding of GEP-NET, PSMA positive mCRPC and RLT.
GEP, gastroenteropancreatic; mCRPC, metastatic castration-resistant prostate cancer; NET, neuroendocrine tumour; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy